She stresses that this caveat matters, as "peptides alone are unlikely to resolve telogen effluvium if the underlying trigger remains unaddressed
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
Article contents Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease Published online by Cambridge University Press: 06 March 2024 Abstract It is inconclusive whether trimethylamine N-oxide (TMAO) and choline and related metabolites, namely trimethylamine (TMA), l-carnitine, betaine and dimethylglycine (DMG), are associated with non-alcoholic fatty liver disease (NAFLD)
They also perform other jobs, such as moving things through the blood and combating dangerous viruses and bacteria
